RecruitingMajor Depressive Disorder

Study of ALTO-300 in MDD

Eligible age

18–70 yrs

Accepts

All genders

Locations

26 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Sponsor: Alto Neuroscience

You may qualify if…

✓ Have a diagnosis of moderate to severe major depressive disorder (MDD)
✓ At Visit 1, currently taking a stable dose of 1 or 2 antidepressants (e.g., SSRI, SNRI, bupropion, or gepirone) for at least 6 weeks with no dose modifications in the past 2 weeks by Visit 2
✓ Willing to comply with all study assessments and procedures
✓ Must not be pregnant or breastfeeding at time of enrollment or throughout study

You may not qualify if…

✕ Evidence of unstable medical condition
✕ Nightly use of sleep medication
✕ Diagnosed bipolar disorder, psychotic disorder, or dementia
✕ Current moderate or severe substance use disorder
✕ Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients
✕ Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device